| Literature DB >> 25988120 |
Cristina Vilaplana-Pérez1, David Auñón2, Libia A García-Flores1, Angel Gil-Izquierdo1.
Abstract
Hydroxytyrosol is one of the main phenolic components of olive oil. It is present in the fruit and leaf of the olive (Olea europaea L.). During the past decades, it has been well documented that this phenolic compound has health benefits and a protective action has been found in preclinical studies against several diseases. Here, we review its bioavailability in human beings and several assays showing significant results related with cardiovascular diseases, cancer, and acquired immunodeficiency syndrome (AIDS). Mechanisms of action include potent anti-oxidant and anti-inflammatory effects, among others. The importance of hydroxytyrosol in protection of low-density lipoproteins and consequently its implication in the reduction of cardiovascular disease risk has been highlighted by the European Food Safety Authority, concluding that 5 mg of hydroxytyrosol and its derivatives should be consumed daily to reach this effect at physiological level. We discuss the potential uses of this compound in supplements, nutraceutic foods, or topical formulations in the disease risk reduction. Finally, we conclude that more studies are needed to sustain or reject many other health claims not yet fully documented and to validate these newly available hydroxytyrosol-based products, because it seems to be a good candidate to reduce the risk of diseases mentioned.Entities:
Keywords: anti-oxidants; disease; hydroxytyrosol; olive oil; phenolic compounds
Year: 2014 PMID: 25988120 PMCID: PMC4428486 DOI: 10.3389/fnut.2014.00018
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Figure 1Hydroxytyrosol and derivatives in olive and olive oil. Adapted from Boskou (10).
Figure 2(A) Oleuropein-glycoside ripening olives and olive oil. (B) Oleuropein-aglycone. (C) Hydroxytryosol. Adapted from Charoenprasert et al. (12).
Protection of LDL from oxidation
| Study type | Anti-oxidant capacity measurement | Conclusion | Reference |
|---|---|---|---|
| Incubation of hydroxytyrosol and two conjugated of HOTYR with isolated LDL | Concentration Vit.E in LDL in presence of copper sulfate with different concentration HOTYR | HOTYR and conjugated, copper sulfate-induced LDL oxidation | ( |
| TBARS level | |||
| Levels of lipid peroxide | |||
| Conjugated dienes formation | |||
| Refined olive oil, common olive oil and virgin olive oil were added to isolated low-density lipoprotein | Conjugated dienes formation was monitored after copper-mediated LDL oxidation | Oils with higher content of phenolic compounds showed the greatest protection of LDL oxidation | ( |
| Dietary study in human beings consuming virgin olive oil | Variables used to study the resistance of LDL: lag time, maximum amount of dienes and maximal oxidation rate | Decrease in LDL cholesterol and LDL oxidation during one week period consuming 25 ml of olive oil. Significantly levels of MUFA and anti-oxidants in LDL | ( |
| Double-blind, crossover, randomized, controlled clinical trial to investigate the effects of olive oil with differences in their phenolic content on LDL oxidation | Ox-LDL was determined in plasma by a sandwich ELISA procedure. The LDL resistance to oxidation was determined by formation of conjugated dienes after copper oxidation of isolated LDL | Decrease | ( |
| Double-blind, randomized, crossover experimental trial in human beings consuming olive oil | Ox-LDL measured by the ELISA method | Significant decrease in plasma oxidized LDL in dose-dependent manner in relation with the phenolic content of the olive oil ingested | ( |
| Multicenter controlled human intervention consuming olive oil with differences in their phenolic content (EUROLIVE) | Ox-LDL measured by a sandwich ELISA procedure using murine monoclonal antibody mAb-4E6 | Significant decrease in plasma oxidized LDL in dose-dependent manner in relation with the phenolic content of the olive oil ingested | ( |
| Dietary study in human beings consuming olive oil with differences in their phenolic content | Ox-LDL measured by enzyme immunoassay using murine monoclonal antibody mAb-4E6 | Dose-dependent response between the intake of polyphenols and the decrease in LDL peroxidation | ( |
| Subsample of EUROLIVE study. Human intervention consuming olive oil with differences in their phenolic content | Ox-LDL in plasma measured by a sandwich ELISA with murine monoclonal antibody mAb-4E6. Anti-oxidant capacity of biological metabolites of phenolic compounds (hydroxytyrosol monosulphate and homovanillic acid sulfate) | Inverse relationship between these metabolites and the degree of LDL oxidation | ( |
HOTYR, hydroxytyrosol; LDL, low-density lipoproteins; Vit. E, vitamin E; CuSO4, copper sulfate; TBARS, thiobarbituric acid-reacting substances; ELISA, enzyme-linked immunosorbent assay; MUFA, monounsaturated fatty acids; Ox-LDL, oxidized low-density lipoproteins.
Chemo-preventive properties of hydroxytyrosol in studies of cancer cell lines
| Cancer | Cell line | Cellular effects | Capacity of HT in cancer | Reference |
|---|---|---|---|---|
| Leukemia | HL60 | Cell cycle arrest (G0/G1 or G2/M) | Antiproliferative | ( |
| Pro-apoptotic | ( | |||
| Inhibition on DNA synthesis | Antiproliferative and pro-apoptotic | ( | ||
| Induction of differentiation | ||||
| Colon cancer | HT29 | G2/M phase cell cycle arrest | Antiproliferative | ( |
| Growth arrest. Stress of the endoplasmic reticulum. Inhibits NF-κB | Antiproliferative and pro-apoptotic | ( | ||
| G2/M phase cycle arrest | ||||
| Caco-2 | Inhibition of p38/CREB phosphorylation and reduction COX-2 expression | Antiproliferative | ( | |
| Inhibition of ERK1/2 phophorilation and cyclin D1 levels | Antiproliferative | ( | ||
| Up-regulating p21 and CCNG2 and down-regulating CCNB1 protein expression | Pro-apoptotic | ( | ||
| SW620 | S phase cell cycle arrest. Inhibition of FAS expression | Antiproliferative and pro-apoptotic | ( | |
| HT115 | Inhibits invasion of cancer colon cells | Anti-invasive | ( | |
| Breast cancer | MCF-7 | G0/G1 cell cycle arrest | Antiproleferative and pro-apoptotic | ( |
| Inhibition of estradiol induced ERK1/2 phosphorylation | Antiproliferative | ( | ||
| SKBR3 | Delay cell cycle in G2/M phase | Antiproliferative and pro-apoptotic | ( | |
| T-47D | ||||
| MB231 | Inhibits CCL5 accumulation and consequently the increase in the ERK1/2-cyclin D1 pro-proliferative pathway | Antiproliferative and pro-apoptotic | ( | |
| Hepatocellular carcinoma | HCC | Induction of G2/M cell cycle arrest and apoptosis | Antiproliferative and pro-apoptotic | ( |
| Suppression of the AKT and NF-κB pathways activation | ||||
| HepG2 | Protection of oxidative stress produced by tBuOOH | ( | ||
| Cholangio-carcinoma | TFK-1 | G2/M phase cell cycle arrest | Antiproliferative and pro-apoptotic | ( |
| KMBC | Inhibition of phospho-ERK | |||
| GBS-SD |
COX-2, cyclooxygenase-2; DNA, deoxyribonucleic acid; ERK1/2, extracellular-signal-regulated kinases 1 and 2; cyclin D1, cyclin-dependent kinase 1; CCNG2 and CCNB1, genes that encode cyclin G2 (inhibitor or cell cycle progression) and cyclin B1 (regulatory protein evolved in mitosis); FAS, fatty acid synthase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; p21, cyclin-dependent kinase inhibitor 1A (also known as p21.